PURPOSE: This phase II study with the topoisomerase I inhibitor topotecan was performed to determine its clinical activity and toxicity in patients with metastatic or locally unresectable colorectal cancer. PATIENTS AND METHODS: Topotecan 1.5 mg/m2 was administered intravenously by 30-minute infusion for 5 days. Fifty-nine patients entered the study, 2 were considered ineligible and 57 were evaluable forresponse and toxicity. RESULTS:Partial response was obtained in 4 of 57 evaluable patients (7%). The median duration of the response was 11 months (range 9.3 to 12.2). This topotecan regimen was very well tolerated. A total of 290 courses were given, with a median of 4 courses per patient (range, 1 to 18). The major toxic effects were leuko- and neutropenia (91%), grade 3-4 in 48% and 79% of courses, respectively, but with only 2 infectious complications. Other side effects were grade 1 alopecia (77%) in 46%, nausea (35%), vomiting (10%), and maculo-papular rash (6%). CONCLUSIONS:Topotecan administered as a daily-times-five regimen has only minor activity as a single-agent therapy in colorectal cancer.
RCT Entities:
PURPOSE: This phase II study with the topoisomerase I inhibitor topotecan was performed to determine its clinical activity and toxicity in patients with metastatic or locally unresectable colorectal cancer. PATIENTS AND METHODS: Topotecan 1.5 mg/m2 was administered intravenously by 30-minute infusion for 5 days. Fifty-nine patients entered the study, 2 were considered ineligible and 57 were evaluable for response and toxicity. RESULTS: Partial response was obtained in 4 of 57 evaluable patients (7%). The median duration of the response was 11 months (range 9.3 to 12.2). This topotecan regimen was very well tolerated. A total of 290 courses were given, with a median of 4 courses per patient (range, 1 to 18). The major toxic effects were leuko- and neutropenia (91%), grade 3-4 in 48% and 79% of courses, respectively, but with only 2 infectious complications. Other side effects were grade 1 alopecia (77%) in 46%, nausea (35%), vomiting (10%), and maculo-papular rash (6%). CONCLUSIONS:Topotecan administered as a daily-times-five regimen has only minor activity as a single-agent therapy in colorectal cancer.
Authors: Peter J Houghton; Richard Lock; Hernan Carol; Christopher L Morton; Richard Gorlick; E Anders Kolb; Stephen T Keir; C Patrick Reynolds; Min H Kang; John M Maris; Catherine A Billups; Mindy X Zhang; Stephen L Madden; Beverly A Teicher; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2011-05-05 Impact factor: 3.167
Authors: Andrew S Mikhail; Elliot B Levy; Venkatesh P Krishnasamy; David L Woods; Juan A Esparza-Trujillo; Ivane Bakhutashvili; Filip Banovac; Paul G Wakim; Ayele H Negussie; Yiqing Tang; Alexander Henman; Sean L Willis; John W Karanian; William F Pritchard; Andrew L Lewis; Bradford J Wood Journal: Cardiovasc Intervent Radiol Date: 2020-08-16 Impact factor: 2.740
Authors: T Kerbusch; G Groenewegen; R A A Mathôt; V M M Herben; W W ten Bokkel Huinink; M Swart; B Ambaum; H Rosing; S Jansen; E E Voest; J H Beijnen; J H M Schellens Journal: Br J Cancer Date: 2004-06-14 Impact factor: 7.640